Glenmark Pharmaceuticals has recalled approximately 1.5 million bottles of Atomoxetine Capsules from the US market after tests found potentially harmful impurities above FDA-approved limits. The medication, used to treat attention deficit hyperactivity disorder (ADHD), was recalled on January 29, 2025. The US Food and Drug Administration classified this as a Class II recall, indicating the products may cause “temporary or medically reversible adverse health consequences” with low probability of serious health issues. According to the FDA’s Enforcement Report, the specific concern is the “presence of N-Nitroso Atomoxetine impurity above the FDA recommended limit.” These compounds, known as nitrosamines, are classified … Continue reading Glenmark Recalls 1.5M ADHD Drug Bottles Over Carcinogen Risk